Company Overview - Sanofi Guojian Pharmaceutical Co., Ltd. is located in the China (Shanghai) Free Trade Zone and was established on January 25, 2002. The company went public on July 22, 2020. Its main business involves the research, production, and sales of antibody drugs [1] - The revenue composition of the company includes 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] Stock Performance - On September 24, the stock price of Sanofi Guojian increased by 5.13%, reaching 55.99 CNY per share, with a trading volume of 273 million CNY and a turnover rate of 0.81%. The total market capitalization is 34.534 billion CNY [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Taixin Fund has a significant position in Sanofi Guojian. The Taixin Medical Service Mixed Initiation A Fund (013072) held 214,800 shares in the second quarter, accounting for 5.15% of the fund's net value, making it the sixth-largest holding [2] - The Taixin Medical Service Mixed Initiation A Fund was established on December 29, 2021, with a latest scale of 31.5558 million CNY. Year-to-date returns are 40.41%, ranking 1725 out of 8173 in its category, while the one-year return is 75.06%, ranking 1478 out of 7996 [2] Fund Manager Information - The fund manager of Taixin Medical Service Mixed Initiation A Fund is Chen Ying, who has been in the position for 3 years and 252 days. The total asset size of the fund is 564 million CNY, with the best return during the tenure being 37.02% and the worst return being -5.65% [3]

Group 1 - The article provides a ranking of open-end funds based on their net asset value growth as of July 7, 2025, highlighting the top 10 funds with significant increases [2][3] - The top-performing funds include 中航混改精选C, 中航混改精选A, and 渤海汇金新动能主题混合A, with net values of 0.7587, 0.7765, and 1.0978 respectively [2] - The bottom-performing funds include 中航优选领航混合发起C and 中航优选领航混合发起A, which saw declines in their net values to 1.6989 and 1.7045 respectively [4] Group 2 - The overall market performance indicates a slight increase in the Shanghai Composite Index, while the ChiNext Index experienced a downward trend [6] - The leading sectors include comprehensive services, multi-financial services, and advertising packaging, all showing growth of over 2% [6] - The article notes that the fund 中航混改精选C has shown rapid net value growth, outperforming the market [6] Group 3 - The top holdings of the funds are concentrated in the real estate sector, with a holding concentration of 86.55% for 中航混改精选C, indicating a strong focus on this industry [7] - The fund's top ten holdings include 万科A and 信达地产, which have shown positive price movements [7] - Conversely, the fund 中航优选领航混合发起C has a lower holding concentration of 82.19% in the pharmaceutical sector, with several holdings experiencing declines [7]